## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)		1											
Name and Address of Reporting Rawcliffe Adrian	2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]					:	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director10% Owner						
(Last) (First) 440 SOUTH BROAD STRI	3. Date of Earliest Transaction (Month/Day/Year) 01/06/2020					[	X Officer (give title below) Other (specify below)  Chief Executive Officer						
(Street) PHILADELPHIA, PA 1914	4. If Amendment, Date Original Filed(Month/Day/Year)					-	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(City) (State)	(Zip)		Table I - Non-Derivative Securities Acqu					Acqui	lired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, if		(Instr. 8)	(A) or Disposed of		of (D) Benefici Reported		unt of Securities ially Owned Following d Transaction(s)		6. Ownership Form:	Beneficial	
				Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)				Ownership (Instr. 4)
American Depositary Share representing Ordinary Share				S		5,900		\$ 1.2 (2)	5,804	3)		D	
(1)  Reminder: Report on a separate lin	e for each class of secu	rities beneficially	y owr	F	erso	ns who	respon			ction of inf			1474 (9-02)
<u>(1)</u>	Table II -	Derivative Secu	rities	F control	Person contain he for	ns who ined in rm disp	respor this for plays a o	m are curren eficiall	not requ tly valid	ired to res	ormation spond unle trol numbe	ss	1474 (9-02)
Reminder: Report on a separate lin  1. Title of 2.	tion 3A. Deemed Execution Date any/Year)	,	5. Non DD See A A (A DD off (I:	s Acquirec	Personante de la containa de la cont	ns who ined in rm disp	respon this for blays a c c, or Bend ble secur sable a Date	eficiallrities) 7. Tit Amo Unde	not required the valid of the and the control of the value of the valu	OMB conf	spond unle	of 10. Ownersh Form of Derivativ Security: Direct (I or Indire	11. Nature of Indirection of Indirec

#### **Reporting Owners**

		Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Rawcliffe Adrian 440 SOUTH BROAD STREET, UNIT 19 PHILADELPHIA, PA 19146	006 X		Chief Executive Officer				

## Signatures

/s/ Adrian George Rawcliffe	01/07/2020
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - Each American Depositary Share ("ADS") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 4, 2019 and which vested on January 4, 2020. Once
- (1) vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from \$1.20 to \$1.2008, inclusive. Upon request, (2) the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote.
- (3) The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds 3,318 ADSs and RSU-style options and other options covering an aggregate of 9,823,200 ordinary shares of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.